Licensing University Technology: A Practical Guide for Companies and Inventors

Summary. What each side can actually agree to, and how to get to signature.

Understand the other side's constraints first

Most failed university licensing negotiations fail because one party is asking for something the other cannot give, and neither says so plainly.

What a technology transfer office cannot do:

• Waive the government's license. Where federal funding was involved, 35 U.S.C. § 202(c)(4) gives the United States a paid-up worldwide license for government purposes. It is not negotiable.
• Waive the domestic manufacturing preference. 35 U.S.C. § 204 conditions any exclusive right to use or sell in the United States on substantial domestic manufacture, absent a waiver from the agency.
• Waive march-in rights under 35 U.S.C. § 203.
• Give up reserved research rights. Institutions retain the right to practice their own inventions for research and education, and to let other nonprofits do so.
• Grant exclusivity without diligence obligations. Failure to take effective steps toward practical application is itself a march-in trigger, so an institution that licenses exclusively without milestones has a compliance problem.
• Assign the patent outright, in most cases, without agency approval.
• Accept unlimited liability. Institutional indemnification and insurance requirements are close to fixed.
• Agree to suppress publication. Delay for patent filing, yes. Suppression, no.

What a company legitimately needs:

• Enough exclusivity to justify the investment
• Freedom to operate in its actual market
• Predictable economics, including a defined path to expand the field
• Control over, or meaningful input into, patent prosecution it is paying for
• The ability to enforce against infringers
• Terms an acquirer will accept in diligence

Where the deal is: the institution trades exclusivity for development commitments, and the company trades development commitments for a defined field with a path to expand. Everything else is detail.

PART ONE: FOR COMPANIES

Step 1 — Diligence the technology and the title

The patent position.

• Read the claims, not the abstract. What is actually covered?
• Prosecution status: issued, pending, provisional? What is the earliest priority date?
• Foreign rights: was there a publication or presentation before filing? Most jurisdictions apply absolute novelty, and a conference poster forfeits foreign rights. Ask directly and get the answer in writing.
• Freedom to operate: what else is in the space?
• Remaining term under 35 U.S.C. § 154, less prosecution time.

The title.

• Do all inventors have present assignment agreements with the institution? The problem identified in Board of Trustees of the Leland Stanford Junior University v. Roche Molecular Systems, Inc., 563 U.S. 776 (2011) is real, and "agree to assign" language creates a gap.
• Were any inventors visiting scholars, industry collaborators, or students subject to other agreements?
• Are assignments recorded?
• Is inventorship correct and documented? An inventorship error is a validity problem.
• Are there co-owners at other institutions? Joint ownership without an inter-institutional agreement is a serious complication, because each co-owner may license non-exclusively without the other's consent.

The funding.

• Which awards supported conception and reduction to practice?
• Was the agency disclosure timely?
• Was title elected?
• Does the patent contain the government support statement?
• Is a § 204 domestic manufacturing commitment going to be a problem for your supply chain? Ask this in week one, not month four.

The technology.

• Development stage, and honestly how far from a product
• Reproducibility: has anyone outside the laboratory made it work?
• What know-how is needed that is not in the patent, and will the inventor be available?

Step 2 — Negotiate the term sheet

Settle the structure before drafting. A term sheet that resolves the following makes the license a two-week exercise:

Two terms worth more than they cost. A right of first negotiation on adjacent fields is often granted cheaply and is valuable if the technology proves broader than expected. Sublicense survival — converting sublicenses to direct licenses if your license terminates — costs the institution little and protects your sublicensees, which matters if you build a partner ecosystem.

One term to fight for. Objective, dated milestones with a defined cure period, rather than a "commercially reasonable efforts" standard. Vague standards feel licensee-friendly and are not: they produce disputes, and a company that has met a written schedule has a defense that a company relying on reasonableness does not.

Step 3 — Handle the Bayh-Dole flow-through

Do not spend time trying to negotiate the statutory conditions away. Do:

• Confirm the domestic manufacture position early. If you will manufacture abroad, the choice is a commitment to domestic manufacture, a waiver application, or a different deal. Waiver applications require showing that domestic manufacture is not commercially feasible or that reasonable efforts to find a domestic licensee failed. They take time.
• Understand what the government license covers. Practice by or on behalf of the United States. It is broader than many companies assume and includes government contractors performing government work.
• Accept the reporting obligation and build a process to supply the data. The institution cannot report what you do not tell it, and its compliance record affects its ability to do business.
• Confirm the government support statement appears in the patents. If it does not, get it corrected before closing.

Step 4 — Plan for the acquirer

Whatever you sign will be diligenced when you are acquired. Ask now:

• Is the license assignable, or does a change of control require consent? Consent rights held by an institution are a real deal risk. Negotiate assignment to an acquirer of all or substantially all of the business as of right.
• Are the milestones achievable by an acquirer with different priorities?
• Is the field definition clear enough that an acquirer's counsel will not flag it?
• Are sublicense obligations documented?
• Is the Bayh-Dole compliance record clean?

PART TWO: FOR INVENTORS AND FOUNDERS

Step 5 — Disclose before you publish

This is the single most consequential thing an academic inventor does, and it is routinely done wrong.

What counts as a public disclosure: a journal article, a conference presentation, a poster, a preprint on a public server, a thesis deposited in a library, a grant abstract published in a public database, a talk to a company without a confidentiality agreement, and — increasingly — a social media thread describing results.

What happens if you disclose first:

• United States: a one-year grace period under 35 U.S.C. § 102(b) preserves your ability to file.
• Most other countries: absolute novelty. Foreign rights are gone.

A provisional application filed before the disclosure preserves everything and is inexpensive. The gap between a provisional filed on Tuesday and a poster presented on Wednesday is the difference between a worldwide patent family and a United States-only one, and it is usually worth six figures or more.

Practical rule: send the abstract to the technology transfer office when you submit it, not when the conference happens.

Step 6 — Write the disclosure properly

The invention disclosure form is the foundation of everything downstream. Include:

• What the invention is, in terms a non-specialist evaluator can assess
• Every funding source that supported conception or reduction to practice, with award numbers
• The conception date, with notebook references
• All contributors, including students, postdoctoral researchers, visitors, and industry collaborators — inventorship is a legal determination, but the office needs the candidates
• Every disclosure already made or scheduled, with dates
• Any material received from outside under a material transfer agreement, which may carry reach-through obligations
• Commercial contacts you already have

Keep laboratory notebooks contemporaneously. Where funding is mixed, notebooks are the only evidence that separates a federally funded conception from an industry-funded one, and that determination controls who owns what.

Step 7 — Manage the conflict honestly

If you are founding a company to license your own invention, you occupy several roles at once. Institutions manage this; the researchers who have trouble are the ones who treat the management as an obstacle rather than as protection.

Disclose early and completely — equity, options, board seats, consulting agreements, and family relationships.

Expect a management plan addressing: whether you may supervise students on work funded by your company; who negotiates the license on the institution's behalf (not you); how your research direction is reviewed; and what you must disclose in publications.

Do not use institutional resources for company work without a documented arrangement. Where the facility was financed with tax-exempt bonds, informal use can create private business use problems for the institution that are far more serious than they appear.

Keep the roles separate in writing. Emails from your institutional account negotiating on behalf of your company are exhibits.

Step 8 — Structure the startup license realistically

• Deferred and capped patent costs. A pre-revenue company cannot reimburse a large international family. Ask for deferral, an annual cap, or conversion of arrears to equity.
• Equity in lieu of cash. Common at low single-digit to low double-digit percentages. Negotiate: anti-dilution (usually none past a defined financing), treatment on change of control, information rights, and — usually best avoided — board representation.
• Milestones tied to financing as well as science. A milestone schedule that ignores runway will be missed.
• A clear field, because your investors will ask, and a vague field reduces valuation.
• Assignment on acquisition as of right. Investors will diligence this.

A negotiation, from both chairs

Halverson Biosciences is a 40-person company developing diagnostic assays. It wants to license a fluorescent probe chemistry from Kestrel State University, invented by Dr. Osian Ramaswamy with support from a federal grant and a foundation award.

The company's diligence, and what it found

Halverson's outside counsel, Priyanka Aldridge-Fontaine, spends three weeks before proposing terms.

The claims. Two issued patents and a pending continuation. The issued claims cover the probe composition; the continuation seeks method-of-use claims that Halverson actually needs. The continuation matters more than the issued patents, and Priyanka makes prosecution control a first-tier issue for that reason.

Foreign rights. Osian presented at a conference eleven months before the priority filing. United States rights are preserved by the grace period under 35 U.S.C. § 102(b); European and Japanese rights are gone. Halverson's market is 60% United States, so this is survivable — but it reduces what Halverson will pay, and Priyanka says so in the term sheet rather than discovering it later.

Title. Kestrel's inventor agreement uses present assignment language, executed at hiring. Assignments are recorded. One co-inventor was a visiting scientist from another university. Priyanka asks for the visiting scientist agreement. It exists, and it uses present assignment language too. This is the Stanford v. Roche check, and it takes twenty minutes when the institution has its house in order.

Funding. Federal grant plus foundation. Agency disclosure was timely; title was elected; the government support statement appears in both issued patents. Clean.

Domestic manufacturing. Halverson manufactures reagents in Ireland. Priyanka raises 35 U.S.C. § 204 in week one, and it becomes the longest-running issue in the negotiation.

The institution's constraints, explained plainly

Kestrel's licensing officer, Marguerite Okonjo-Vance, responds to Halverson's opening term sheet with a short memorandum explaining what she cannot do and why. It is unusual and it shortens the negotiation by a month.

• The government license under 35 U.S.C. § 202(c)(4) is statutory.
• Reserved research rights for Kestrel and other nonprofits are institutional policy and will not move.
• Milestones are required, and she explains the march-in connection under 35 U.S.C. § 203 rather than presenting them as commercial preference.
• Indemnification and insurance requirements are set by the university's risk office.
• Assignment of the patents outright would require agency approval; an exclusive license is the practical equivalent.

Where the real negotiation happened

Domestic manufacturing. Halverson's Irish facility is its only reagent line. Three options were on the table:

1. Commit to substantial United States manufacture — capital Halverson does not have.
2. Apply for a waiver, showing that domestic manufacture is not commercially feasible — slow and uncertain.
3. Restructure the grant so that the exclusive right to use or sell in the United States is narrower.

They chose a variant of option two, with a fallback: Halverson takes an exclusive worldwide license, commits to filing a waiver application with agency support from Kestrel, and — if the waiver is denied — the United States exclusivity converts to co-exclusive while Halverson retains exclusivity elsewhere. Kestrel agreed because it preserves compliance; Halverson agreed because it preserves the deal.

Prosecution control of the continuation. Halverson is paying and needs the method claims. Kestrel wants claims broad enough to support other fields. Resolution: Halverson instructs counsel on the continuation and pays; Kestrel receives copies of all correspondence, may comment, and holds approval over abandonment and over any amendment that would surrender scope outside Halverson's field.

Net sales. Halverson sells assay kits containing the probe plus buffers, plates, and software. A royalty on the full kit price would overpay dramatically. They agreed a combination-product allocation based on the relative cost of the probe component, with a floor so the allocation cannot go below 20% of kit price.

Milestones. Analytical validation within 12 months; clinical validation within 30 months; first commercial sale within 48 months. A 180-day cure period, and one 12-month extension available on a showing of good-faith diligence and payment of an extension fee.

What each side would say afterward

Marguerite: "Explaining our constraints in writing at the start saved a month. Companies argue with statutory terms when nobody has told them the terms are statutory."

Priyanka: "The domestic manufacturing question in week one was the whole negotiation. If we had found it in month four, the deal would have died."

Osian: "I gave the conference talk because I did not know a poster was a publication. It cost my university the European market."

Inter-institutional agreements

When inventors at two institutions collaborate, the resulting patent is jointly owned — and joint ownership of a United States patent is a difficult default: each co-owner may practice and license non-exclusively without the other's consent and without accounting. An exclusive license from one co-owner alone is not exclusive.

The fix is an inter-institutional agreement, executed before licensing and ideally before filing. Its terms:

Lead institution. One institution takes the lead on prosecution and licensing. The other reviews and consents to defined actions.

Cost sharing. Proportional, or borne by the lead with reimbursement from income. Address what happens if one institution declines to fund a country.

Income sharing. Usually proportional to inventive contribution, agreed at the outset. Renegotiating after money arrives is unpleasant and slow.

Licensing authority. The lead may grant exclusive licenses binding both, subject to defined approvals — a materially important delegation, because without it no exclusive license is possible.

Bayh-Dole compliance. Which institution reports, elects, and files. Both may have obligations if both received federal funding.

Disputes and withdrawal. What happens if one institution wants to abandon a patent the other values.

Companies should always ask whether an inter-institutional agreement exists and should review it. A license from one co-owner without one is worth far less than it appears, and this is a common and expensive diligence finding.

A negotiation sequence

Realistic total: three to five months. Faster is possible with a simple non-exclusive license; slower is common where equity, sponsored research, or multiple institutions are involved.

Budget expectations

The patent cost line is the one that surprises startups. Ask for the actual historical spend and the projected annual cost before signing anything.

Mistakes that recur

Presenting before filing. Destroys foreign rights and cannot be undone.

Discovering the domestic manufacturing requirement in month four. Ask in week one.

Assuming "exclusive" means exclusive. It is subject to the government license and reserved research rights.

Accepting "commercially reasonable efforts" milestones. Vague standards produce disputes and give the licensee no defense.

Ignoring the net sales definition while negotiating the royalty rate. The definition moves more money.

Failing to check inventor assignments. Stanford v. Roche problems are found in acquisition diligence.

Missing joint ownership with another institution. Each co-owner can license non-exclusively without the other, which can destroy the exclusivity you paid for.

Not planning for the acquirer. Consent rights and unachievable milestones become deal issues later.

Treating conflict-of-interest management as a formality. It protects the founder more than anyone.

Sponsored research: getting the terms right before the work starts

A company funding research at an institution is buying a relationship, not a result, and the agreement should reflect that.

The terms that matter, in order of how often they go wrong:

1. Intellectual property ownership. The workable default: each party owns inventions made solely by its personnel; joint inventions are jointly owned. The company's rights come through an option, not through ownership. Companies that insist on owning results are asking the institution to do something that can jeopardize its exempt status under 26 U.S.C. § 501 and generate unrelated business taxable income under 26 U.S.C. § 511, and — where the laboratory sits in a bond-financed building — can create private business use problems for the bonds.

2. The option terms. This is where a company should spend its negotiating capital. An option to negotiate "on commercially reasonable terms to be agreed" is nearly worthless; it is an agreement to agree. Far better: an option to a license on pre-agreed terms set out in an exhibit — field, royalty range, milestone framework, and diligence structure — leaving only the specifics to be filled in. Institutions accept this more often than companies expect, because it reduces their negotiating burden too.

3. Publication. The institution will not accept suppression. The workable structure: the institution provides manuscripts and abstracts to the company 30 to 60 days before submission; the company may request removal of its confidential information and a delay of up to an additional 30 to 90 days to permit patent filing; and thereafter publication proceeds.

4. Background intellectual property. Each party keeps its own. The company should get a license to the institution's background rights to the extent necessary to practice the funded results — otherwise it may license a result it cannot use without a separate license to an underlying platform patent. This is a common and avoidable trap.

5. Scope of the funded work. Define it narrowly, in a statement of work attached as an exhibit. An agreement covering "research in Dr. X's laboratory" sweeps in inventions from unrelated and separately funded projects, and no institution should sign it and no company should want it — because the resulting entanglement makes the company's own rights unclear.

6. Personnel. Name the principal investigator and address what happens if they leave.

7. Publicity. Neither party uses the other's name or marks without consent. Institutions are particularly careful here, and companies routinely violate it in press releases.

8. Term, budget, and reporting. Including what happens to unspent funds and to equipment purchased with the award.

A note on federal funding overlap. If the laboratory also holds federal funding, inventions may be subject inventions under Bayh-Dole regardless of the company's contribution. The sponsored research agreement cannot override the statute, and the company's option is necessarily subject to the government's rights. Say so in the agreement rather than letting the company discover it when it exercises the option.

Valuing a university license

Both sides benefit from a defensible number, and "what did the last deal get" is a poor substitute for analysis.

Start with what is actually being transferred. An issued patent with claims covering a validated product is a different asset from a provisional covering a laboratory result nobody outside the group has reproduced. Most university technology is the second kind, and pricing it like the first is how negotiations stall.

Adjust for stage. Royalty rates and upfront payments in university licensing correlate strongly with development stage, because the licensee is buying the right to spend a great deal more money. A rough ordering, from lowest to highest institutional take: a concept with a provisional; a reduced-to-practice invention with issued claims; a validated prototype; a technology with third-party replication; and one with regulatory or customer validation.

Adjust for what is missing. Each of these reduces value, and each should be priced rather than argued about:

Adjust for what the institution brings. Continued inventor involvement, access to the laboratory's ongoing work, a right of first negotiation on improvements, and the institution's willingness to support a waiver application or an enforcement action all have real value and are often given away for free because nobody priced them.

Model the whole life. Upfront plus maintenance plus milestones plus royalties over the patent term, discounted, against the development cost and the probability of reaching market. For an early-stage technology the probability term dominates everything else, which is why milestone-weighted structures make more sense than large upfronts for both parties.

Benchmark carefully. Published royalty surveys are useful for ranges by industry and stage, and misleading if applied without adjusting for exclusivity, field breadth, and what stage the technology had reached at signing.

Managing the license after signature

The license is the beginning of a relationship that will last as long as the patents, and most of the value is destroyed or preserved after signing.

For the licensee

• Calendar everything: milestone dates, reporting deadlines, maintenance fees, patent annuities, and the cure periods attached to each. Missed milestones are the most common cause of university license termination, and they are almost always administrative rather than substantive failures.
• Report accurately and on time, including the utilization information the institution needs for its own Bayh-Dole reporting. An institution that must chase a licensee for data it owes the government becomes an unhelpful institution.
• Update the development plan annually and use it. A written record of diligence is the defense if a milestone is missed.
• Keep the royalty calculation documented. Combination-product allocations get audited, and reconstructing three years of allocations under audit pressure is expensive.
• Notify the institution of sublicenses and pay the income share promptly. Sublicense income disputes are the most common source of audit findings.
• Maintain the relationship with the inventor. Consulting agreements lapse, laboratories move on, and the know-how you need in year three lives in someone's memory.

For the institution

• Track milestones actively, not at renewal. A licensee that has quietly stopped work is a march-in exposure as well as a lost opportunity, and the conversation is easier at month six than at month thirty.
• Collect utilization data and report it. This is the obligation most often neglected and most visible in an audit.
• Audit royalties periodically. Not adversarially — most underreporting is error — but consistently. A licensee that knows an audit happens reports more carefully.
• Manage field boundaries. Where multiple licensees hold adjacent fields, ambiguity becomes a dispute the institution is caught in the middle of. Document interpretations as they arise.
• Handle termination deliberately. Where a licensee has stopped performing, the options are conversion to non-exclusive, field reduction, or termination, and each has consequences for sublicensees and for the technology's prospects. Terminating without a plan for what happens next leaves the technology shelved with a worse record than before.

For both

• Keep a single point of contact on each side, and update it when people leave. A surprising number of license disputes begin with a notice sent to someone who left two years earlier.
• Address amendments in writing. Informal accommodations — an extended milestone, a waived report — become disputes about whether the license was modified.

Frequently asked questions

How do we handle improvements made after the license? Address it in the license. Improvements made by the licensee are typically the licensee's. Improvements made in the inventor's laboratory are the institution's, and the licensee should negotiate a right of first negotiation or an option covering improvements arising in a defined field during a defined period. Institutions resist open-ended grant-backs, because they would encumber future research indefinitely.

What if the technology needs a second patent family we do not control? Blocking positions are common and should be identified in diligence. The options are a license from the third party, a design-around, a cross-license, or — where the blocking patent is held by another institution and the inventors collaborated — an inter-institutional arrangement. Discovering a blocking patent after signing is one of the more expensive diligence failures.

Can a foreign company license from a United States university? Yes, subject to 35 U.S.C. § 204 for any exclusive right to use or sell in the United States, and subject to export control review where the technology is controlled. Both issues should be raised in the first substantive call.

Can we buy the patent instead of licensing it? Usually not from a nonprofit without agency approval, where federal funding was involved. An exclusive license with all substantial rights can achieve much of the same commercial effect, including standing to sue.

What if we want a field the institution has already licensed? Ask for the boundary in writing. Fields are frequently defined loosely, and overlapping grants are a known source of disputes. If your intended use is near a boundary, get an interpretation before signing.

Will the institution sue infringers for us? Usually not at its own cost. Negotiate the right to enforce, joinder cooperation, and recovery sharing. An exclusive licensee holding all substantial rights may have standing alone; a narrower licensee must join the institution.

How much equity will the institution want? It varies widely; low single digits to low double digits at formation is common, generally in exchange for reduced cash consideration. Model the dilution before agreeing.

Do we have to pay for patents in countries we do not care about? Negotiate country selection. A common structure gives the licensee the choice of countries and the corresponding cost, with the institution free to file elsewhere at its own expense and to license those rights separately.

What if the inventor leaves the university? The license is with the institution, not the inventor. Address separately whether the inventor will be available for consulting, and put it in a written agreement rather than assuming goodwill.

Can we get the know-how too? Ask. Much of what makes an early-stage technology work is unpatented. A consulting agreement with the inventor, or a technology transfer plan with defined deliverables, is worth negotiating alongside the license.

Where to get help

The technology transfer office itself. Underused by companies, who often treat it as an adversary. A good licensing officer knows the technology's history, the inventors, the funding, the prior disclosures, and the institution's constraints, and will tell you most of it if asked directly.

Institutional policies, which are usually public. Patent policy, conflict of interest policy, and the standard license terms are frequently posted. Reading them before the first meeting is worth an hour and prevents proposals that cannot be accepted.

The funding agreement itself. 35 U.S.C. § 206 directs the promulgation of standard patent rights clauses, and the clauses in 37 C.F.R. Part 401 are what actually bind. Agencies add supplemental terms. Read the clause in the specific award rather than the statute.

Agency technology transfer offices. For federally owned inventions and for waiver questions under 35 U.S.C. § 204, the agency's technology transfer contact is the right first call, and agencies are generally willing to discuss a waiver's prospects informally before an application is filed.

Federal laboratory partnerships. Where the technology sits in a national laboratory rather than a university, the framework is different — 15 U.S.C. § 3710a for cooperative agreements and 35 U.S.C. § 209 for licensing federally owned inventions — and the laboratory's partnership office manages it.

Professional associations. Technology transfer professionals maintain associations that publish licensing surveys, model agreements, and practice guidance. The royalty survey data is the standard benchmarking source, and the model agreements are useful starting points that are not, and should not be treated as, forms.

Counsel with the practice. University licensing rewards familiarity with institutional constraints more than general licensing expertise. A lawyer who has never encountered 35 U.S.C. § 204 will find it in month four.

A short note on why this system is contested

Practitioners should know the policy argument, because clients raise it and because it shapes proposed changes to the rules.

The case for Bayh-Dole is the one Congress made in 35 U.S.C. § 200: before 1980, federally funded inventions sat unlicensed because no company would invest development capital without exclusivity. Giving institutions title, and letting them grant exclusive licenses with development obligations, moved research into products. Supporters point to the industries that grew from university licensing and to the roughly 100-fold increase in university patenting and startup formation since.

The case against has several strands. That taxpayers fund the research and then pay again at monopoly prices for the resulting products, most visibly in pharmaceuticals. That the patenting of upstream research tools impedes downstream research — the anticommons argument. That institutions have been drawn toward revenue-seeking behavior at some cost to their research missions. And that march-in rights, the statute's own safety valve, have never once been exercised, which supporters read as evidence the system works and critics read as evidence the valve is welded shut.

The live policy question is whether pricing can support march-in. Petitions have argued that a drug priced beyond reach is not "available to the public on reasonable terms" and therefore has not achieved practical application under 35 U.S.C. § 203. Agencies have consistently declined, reasoning that availability, not price, is the statutory measure. Proposed frameworks would make price a factor. Whether one is adopted, and whether it survives challenge, is the most consequential open question in the field.

What a practitioner should do with this. Nothing, in the ordinary course — the statute is what it is, and licenses should be negotiated against current law. But the debate explains why institutions insist on diligence obligations they might otherwise trade away, why domestic manufacturing commitments are enforced more carefully than they once were, and why a licensee's development record is worth documenting even when no one is asking for it.

Related documents

• University Technology Transfer and Bayh-Dole: Who Owns Federally Funded Inventions
• Bayh-Dole Compliance Checklist: A Practical Checklist
• Technology Transfer Toolkit: Invention Reporting, License Terms, and Sponsored Research
• How to License Your Patent: From Valuation to Term Sheet
• Patent Ownership, Assignments, and Standing: Chain of Title Problems That Sink Cases
• How to Prepare an Invention Disclosure for Your Patent Attorney
• Startup Formation and Fundraising Toolkit: A Roadmap and Resource Guide
• Employee Invention Assignment Agreements: Drafting for Enforceability Across Jurisdictions